Meeting
2020 ASCO Virtual Scientific Program
Phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent head and neck squamous cell carcinoma.
Authors
Michelle Echevarria
Department of Radiation Oncology, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL
Michelle Echevarria , Christine H. Chung , Kedar Kirtane , Jameel Muzaffar , John Arrington , Joaquim Farinhas , Jimmy J. Caudell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02158234
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6543)
DOI
10.1200/JCO.2020.38.15_suppl.6543
Abstract #
6543
Poster Bd #
204
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC).
First Author: V. Papadimitrakopoulou
Poster
2021 ASCO Annual Meeting
Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.
First Author: Christophe Le Tourneau
Poster
2023 ASCO Annual Meeting
XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
First Author: Robert L. Ferris
Poster
2023 ASCO Annual Meeting
Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.
First Author: Colette Shen